Product Code: GVR-4-68039-808-0
Real World Evidence Solutions Market Growth & Trends:
The global real world evidence solutions market size is expected to reach USD 4.6 billion by 2030, registering a CAGR of 8.4% from 2024 to 2030, according to a new report by Grand View Research, Inc. Key driving factors of the market include growing applications of RWE in several fields, favorable government regulations, technological advancements, and a shift from volume to value-based care. Furthermore, a growing number of strategic initiatives by organizations are anticipated to positively influence market growth.
In March 2024, DARWIN EU, the Data Analysis & Real World Interrogation Network, announced plans to enhance its capacity for RWD studies by adding 10 new data partners within the year. With a network of 20 institutions spanning 13 European countries, DARWIN EU collaborates with public & private entities to derive RWE from diverse sources, including hospitals, primary care facilities, health insurance databases, registries, and biobanks.
This RWE supports regulatory activities of the EMA and national regulators across the EU. Leveraging data from approximately 130 million patients across Europe, DARWIN EU aims to deliver robust evidence through RWD studies. Notably, the network employs a common data model to standardize data interpretation while ensuring data privacy through local storage and analysis by data partners. This approach prioritizes data protection and facilitates the efficient execution of large-scale, multi-database studies.
Furthermore, major consumers of RWE are pharmaceutical and medical device companies. This is because it can provide value across the entire product lifecycle. It has applications across life science research, clinical trials & studies, post-market surveillance, and regulatory requirements. In life science research, RWE can inform pretrial study design by assisting researchers in identifying potential patients and creating proper inclusion criteria for clinical trials. Within clinical trials & studies, it helps overcome traditional clinical trials' limitations by providing information about a broader cross-section of society and supplementing traditional outcome measures, such as patient-reported outcome surveys.
Moreover, medical product designers are using RWD & RWE to aid clinical trial designing (e.g., pragmatic clinical trials, large simple trials) and observational studies to produce innovative, new treatment approaches. Thus, technology plays a significant role in healthcare decisions, which, in turn, promotes segment growth. For instance, in July 2023, Johnson & Johnson gained approval for certain cardiac ablation devices for fluoroscopy-free use following a prospective observational registry study-an instance of the agency employing RWE in device reviews.
In addition, several companies are focusing on RWD collection to enhance RWE in the neurology sector. For instance, in September 2023, OM1 announced a curated research-grade dataset focused on Parkinson's disease (PD) as part of its Mental Health and Neuroscience RWD Network expansion. This dataset features premium data from over 7,000 individuals with PD, tracked prospectively by neurologists, along with data from 700,000 PD patients in the OM1 Real-World Data Cloud. The RWE insights from this comprehensive data are anticipated to enhance understanding of PD patient journeys, leading to improved care & outcomes.
Real World Evidence Solutions Market Report Highlights:
- Based on component, the services segment led the market with the largest share of 57.7% in 2023 owing to its increasing demand over the forecast period
- Based on application, the drug development and approvals segment dominated the market with a revenue share of 28.7% in 2023 owing to the rising adoption of RWE solutions in pharmaceutical companies for this application
- Based on end-use, healthcare companies dominated the market with the largest share of 32.8% in 2023. The growth is due to growing use of RWE solutions in several fields by pharmaceutical, biopharmaceutical, and medical device companies
- Based on therapeutic area, the oncology segment led the market with a share of 22.8% in 2023 owing to increased use of RWE solutions to develop therapies for cancer care by research organizations and pharmaceutical companies
- North America led the global market with a revenue share of 43.5% in 2023 owing to the presence of major players in the region. Asia Pacific is expected to be the fastest-growing regional market from 2024 to 2030 owing to the presence of contract research organizations in the region
Table of Contents
Chapter 1 Research Methodology & Scope
- 1.1 Market Segmentation & Scope
- 1.1.1 Estimates & Forecast Timeline
- 1.2 Research Methodology
- 1.3 Information Procurement
- 1.3.1 Purchased Database:
- 1.3.2 GVR's Internal Database
- 1.3.3 Secondary Sources
- 1.3.4 Primary Research:
- 1.3.5 Details Of Primary Research
- 1.4 Information Or Data Analysis
- 1.4.1 Data Analysis Models
- 1.5 Market Formulation & Validation
- 1.6 Model Details
- 1.6.1 Consensus-based Estimates & Forecasting
- 1.6.1.1 Commodity Flow Analysis
- 1.6.1.2 Top-down Market Estimation
- 1.6.1.3 Country-based Segment Share Calculation
- 1.6.2 Multivariate Analysis
- 1.6.3 Real World Evidence Solutions Market: Cagr Calculation
- 1.7 List Of Secondary Sources
- 1.8 Objectives
- 1.8.1 Objective - 1
- 1.8.2 Objective - 2
Chapter 2 Executive Summary
- 2.1 Market Snapshot
- 2.2 Segment Snapshot
- 2.3 Competitive Landscape Snapshot
Chapter 3 Real World Evidence (Rwe) Solutions Market Variables Trends & Scope
- 3.1 Market Lineage Outlook
- 3.1.1 Parent Market Outlook
- 3.1.2 Ancillary Market Outlook
- 3.2 Market Dynamics
- 3.2.1 Market Driver Analysis
- 3.2.1.1 Favorable Government Regulations
- 3.2.1.2 Rising Applications Of Real-world Evidence (RWE) In Various Fields
- 3.2.1.3 Technological Advancements
- 3.2.1.4 Increasing Initiatives By Organizations
- 3.2.2 Market Restraint Analysis
- 3.2.2.1 Lack Of Access To Healthcare Data
- 3.3 Market Opportunity Analysis
- 3.3.1 Gap Between Research And Practice
- 3.4 Market Challenges Analysis
- 3.4.1 Issues With Rwe Validation, Operations, And Technologies
- 3.5 Real World Evidence (Rwe) Solutions: Market Analysis Tools
- 3.5.1 Industry Analysis - Porter's
- 3.5.2 Industry Analysis - Pestle
- 3.6 Regulatory Framework
- 3.6.1 North America
- 3.6.2 Asia Pacific
- 3.6.3 Europe - Regulatory Framework
- 3.7 Pricing Model Analysis
- 3.7.1 Pay Per Usage
- 3.7.2 Pay Per Patient Record
- 3.7.3 Annual/monthly Subscription
- 3.8 Case Study
- 3.8.1 Case Study 1:- OM1 Partnered With Healthcare Facilities To Collect Medical Data At A Clinical Level
- 3.8.2 Case Study 2:- Verana Health
Chapter 4 Real World Evidence (Rwe) Solutions: COVID-19 Impact
- 4.1 COVID-19 Disease Prevalence
- 4.2 Impact Of COVID-19 On Market Players And Strategies Implemented
- 4.2.1 Ibm
- 4.2.2 Pharmaceutical Product Development (PPD)
- 4.2.3 Iqvia
- 4.3 Opportunity Analysis
Chapter 5 Real World Evidence Solutions Market: Component Analysis
- 5.1 Component Business Analysis
- 5.2 Real World Evidence Solutions Market: Component Movement Analysis
- 5.3 Services
- 5.3.1 Services Market Estimates And Forecasts, 2018 - 2030 (USD Million)
- 5.4 Data Sets
- 5.4.1 Data Sets Market Estimates And Forecasts, 2018 - 2030 (USD Million)
- 5.4.2 Clinical Settings Data
- 5.4.2.1 Clinical Settings Data Market Estimates And Forecasts, 2018 - 2030 (USD Million)
- 5.4.3 Claims Data
- 5.4.3.1 Claims Data Market Estimates And Forecasts, 2018 - 2030 (USD Million)
- 5.4.4 Pharmacy Data
- 5.4.4.1 Pharmacy Data Market Estimates And Forecasts, 2018 - 2030 (USD Million)
- 5.4.5 Patient-powered Data
- 5.4.5.1 Patient-powered Data Market Estimates And Forecasts, 2018 - 2030 (USD Million)
Chapter 6 Real World Evidence Solutions Market: Application Analysis
- 6.1 Application Business Analysis
- 6.2 Real World Evidence Solutions Market: Application Movement Analysis
- 6.3 Drug Development & Approvals
- 6.3.1 Drug Development & Approvals Market Estimates And Forecasts, 2018 - 2030 (USD Million)
- 6.4 Medical Device Development & Approvals
- 6.4.1 Medical Device Development & Approvals Market Estimates And Forecasts, 2018 - 2030 (USD Million)
- 6.5 Reimbursement/coverage & Regulatory Decision-making
- 6.5.1 Reimbursement/coverage & Regulatory Decision-making Market Estimates And Forecasts, 2018 - 2030 (USD Million)
- 6.6 Post-market Safety & Adverse Events Monitoring
- 6.6.1 Post-market Safety & Adverse Events Monitoring Market Estimates And Forecasts, 2018 - 2030 (USD Million)
Chapter 7 Real World Evidence Solutions Market: End Use Analysis
- 7.1 End Use Business Analysis
- 7.2 Real World Evidence Solutions Market: End Use Movement Analysis
- 7.3 Healthcare Companies
- 7.3.1 Healthcare Companies Market Estimates And Forecasts, 2018 - 2030 (USD Million)
- 7.3.2 Clinical Research Market Estimates And Forecasts, 2018 - 2030 (USD Million)
- 7.3.3 Commercial Market Estimates And Forecasts, 2018 - 2030 (USD Million)
- 7.3.4 Heor Market Estimates And Forecasts, 2018 - 2030 (USD Million)
- 7.3.5 Others Market Estimates And Forecasts, 2018 - 2030 (USD Million)
- 7.4 Healthcare Payers
- 7.4.1 Healthcare Payers Market Estimates And Forecasts, 2018 - 2030 (USD Million)
- 7.5 Healthcare Providers
- 7.5.1 Healthcare Providers Market Estimates And Forecasts, 2018 - 2030 (USD Million)
- 7.6 Others
- 7.6.1 Others Market Estimates And Forecasts, 2018 - 2030 (USD Million)
Chapter 8 Real World Evidence Solutions Market: Therapeutic Area Analysis
- 8.1 Therapeutic Area Business Analysis
- 8.2 Real World Evidence Solutions Market: Therapeutic Area Movement Analysis
- 8.3 Oncology
- 8.3.1 Oncology Market Estimates And Forecasts, 2018 - 2030 (USD Million)
- 8.4 Cardiology
- 8.4.1 Cardiology Market Estimates And Forecasts, 2018 - 2030 (USD Million)
- 8.5 Neurology
- 8.5.1 Neurology Market Estimates And Forecasts, 2018 - 2030 (USD Million)
- 8.6 Diabetes
- 8.6.1 Diabetes Market Estimates And Forecasts, 2018 - 2030 (USD Million)
- 8.7 Psychiatry
- 8.7.1 Psychiatry Market Estimates And Forecasts, 2018 - 2030 (USD Million)
- 8.8 Respiratory
- 8.8.1 Respiratory Market Estimates And Forecasts, 2018 - 2030 (USD Million)
- 8.9 Other Therapeutic Areas
- 8.9.1 Other Therapeutic Areas Market Estimates And Forecasts, 2018 - 2030 (USD Million)
Chapter 9 Real World Evidence (Rwe) Solutions Market: Regional Market Analysis, By Component, Application, Therapeutic Area, And End Use 2018 - 2030 (USD Million)
- 9.1 Regional Market Share Analysis, 2023 & 2030
- 9.2 Regional Market Snapshot
- 9.3 Regional Market Snapshot
- 9.4 North America
- 9.4.1 North America Real World Evidence Solutions Market Estimates And Forecasts, 2018 - 2030 (USD Million)
- 9.4.2 U.S.
- 9.4.2.1 Country Dynamics
- 9.4.2.2 U.S. Real World Evidence Solutions Market Estimates And Forecasts, 2018 - 2030 (USD Million)
- 9.4.3 Canada
- 9.4.3.1 Country Dynamics
- 9.4.3.2 Canada Real World Evidence Solutions Market Estimates And Forecasts, 2018 - 2030 (USD Million)
- 9.5 Europe
- 9.5.1 Europe Real World Evidence Solutions Market Estimates And Forecasts, 2018 - 2030 (USD Million)
- 9.5.2 Germany
- 9.5.2.1 Country Dynamics
- 9.5.2.2 Germany Real World Evidence Solutions Market Estimates And Forecasts, 2018 - 2030 (USD Million)
- 9.5.3 France
- 9.5.3.1 Country Dynamics
- 9.5.3.2 France Real World Evidence Solutions Market Estimates And Forecasts, 2018 - 2030 (USD Million)
- 9.5.4 Uk
- 9.5.4.1 Country Dynamics
- 9.5.4.2 Uk Real World Evidence Solutions Market Estimates And Forecasts, 2018 - 2030 (USD Million)
- 9.5.5 Italy
- 9.5.5.1 Country Dynamics
- 9.5.5.2 Italy Real World Evidence Solutions Market Estimates And Forecasts, 2018 - 2030 (USD Million)
- 9.5.6 Spain
- 9.5.6.1 Country Dynamics
- 9.5.6.2 Spain Real World Evidence Solutions Market Estimates And Forecasts, 2018 - 2030 (USD Million)
- 9.5.7 Denmark
- 9.5.7.1 Country Dynamics
- 9.5.7.2 Denmark Real World Evidence Solutions Market Estimates And Forecasts, 2018 - 2030 (USD Million)
- 9.5.8 Sweden
- 9.5.8.1 Country Dynamics
- 9.5.8.2 Sweden Real World Evidence Solutions Market Estimates And Forecasts, 2018 - 2030 (USD Million)
- 9.5.9 Norway
- 9.5.9.1 Country Dynamics
- 9.5.9.2 Norway Real World Evidence Solutions Market Estimates And Forecasts, 2018 - 2030 (USD Million)
- 9.5.10 Asia Pacific Real World Evidence Solutions Market Estimates And Forecasts, 2018 - 2030 (USD Million)
- 9.5.11 Japan
- 9.5.11.1 Country Dynamics
- 9.5.11.2 Japan Real World Evidence Solutions Market Estimates And Forecasts, 2018 - 2030 (USD Million)
- 9.5.12 China
- 9.5.12.1 Country Dynamics
- 9.5.12.2 China Real World Evidence Solutions Market Estimates And Forecasts, 2018 - 2030 (USD Million)
- 9.5.13 India
- 9.5.13.1 Country Dynamics
- 9.5.13.2 India Real World Evidence Solutions Market Estimates And Forecasts, 2018 - 2030 (USD Million)
- 9.5.14 Australia
- 9.5.14.1 Country Dynamics
- 9.5.14.2 Australia Real World Evidence Solutions Market Estimates And Forecasts, 2018 - 2030 (USD Million)
- 9.5.15 South Korea
- 9.5.15.1 Country Dynamics
- 9.5.15.2 South Korea Real World Evidence Solutions Market Estimates And Forecasts, 2018 - 2030 (USD Million)
- 9.5.16 Thailand
- 9.5.16.1 Country Dynamics
- 9.5.16.2 Thailand Real World Evidence Solutions Market Estimates And Forecasts, 2018 - 2030 (USD Million)
- 9.6 Latin America
- 9.6.1 Latin America Real World Evidence Solutions Market Estimates And Forecasts, 2018 - 2030 (USD Million)
- 9.6.2 Brazil
- 9.6.2.1 Country Dynamics
- 9.6.2.2 Brazil Real World Evidence Solutions Market Estimates And Forecasts, 2018 - 2030 (USD Million)
- 9.6.3 Mexico
- 9.6.3.1 Country Dynamics
- 9.6.3.2 Mexico Real World Evidence Solutions Market Estimates And Forecasts, 2018 - 2030 (USD Million)
- 9.6.4 Argentina
- 9.6.4.1 Country Dynamics
- 9.6.4.2 Argentina Real World Evidence Solutions Market Estimates And Forecasts, 2018 - 2030 (USD Million)
- 9.7 Mea
- 9.7.1 Mea Real World Evidence Solutions Market Estimates And Forecasts, 2018 - 2030 (USD Million)
- 9.7.2 South Africa
- 9.7.2.1 Country Dynamics
- 9.7.2.2 South Africa Real World Evidence Solutions Market Estimates And Forecasts, 2018 - 2030 (USD Million)
- 9.7.3 Saudi Arabia
- 9.7.3.1 Country Dynamics
- 9.7.3.2 Saudi Arabia Real World Evidence Solutions Market Estimates And Forecasts, 2018 - 2030 (USD Million)
- 9.7.4 Israel
- 9.7.4.1 Country Dynamics
- 9.7.4.2 Israel Real World Evidence Solutions Market Estimates And Forecasts, 2018 - 2030 (USD Million)
- 9.7.5 Uae
- 9.7.5.1 Country Dynamics
- 9.7.5.2 Uae Real World Evidence Solutions Market Estimates And Forecasts, 2018 - 2030 (USD Million)
- 9.7.6 Kuwait
- 9.7.6.1 Country Dynamics
- 9.7.6.2 Kuwait Real World Evidence Solutions Market Estimates And Forecasts, 2018 - 2030 (USD Million)
Chapter 10 Competitive Analysis
- 10.1 Market Participation Categorization
- 10.2 Strategic Mapping
- 10.3 Public Companies
- 10.4 Private Companies
Chapter 11 Company Profiles
- 11.1 IQVIA Inc.
- 11.1.1 Company Overview
- 11.1.2 Financial Performance
- 11.1.3 Product Benchmarking
- 11.1.4 Strategic Initiatives
- 11.2 IBM
- 11.2.1 Company Overview
- 11.2.2 Financial Performance
- 11.2.3 Product Benchmarking
- 11.2.4 Strategic Initiatives
- 11.3 PPD, Inc. (Acquired by Thermo Fisher Scientific, Inc.)
- 11.3.1 Company Overview
- 11.3.2 Financial Performance
- 11.3.3 Product Benchmarking
- 11.3.4 Strategic Initiatives
- 11.4 Parexel International (MA) Corporation
- 11.4.1 Company Overview
- 11.4.2 Financial Performance
- 11.4.3 Product Benchmarking
- 11.4.4 Strategic Initiatives
- 11.5 PerkinElmer Inc.
- 11.5.1 Company Overview
- 11.5.2 Financial Performance
- 11.5.3 Product Benchmarking
- 11.5.4 Strategic Initiatives
- 11.6 ICON plc
- 11.6.1 Company Overview
- 11.6.2 Financial Performance
- 11.6.3 Product Benchmarking
- 11.6.4 Strategic Initiatives
- 11.7 Oracle
- 11.7.1 Company Overview
- 11.7.2 Financial Performance
- 11.7.3 Product Benchmarking
- 11.7.4 Strategic Initiatives
- 11.8 Syneos Health
- 11.8.1 Company Overview
- 11.8.2 Financial Performance
- 11.8.3 Product Benchmarking
- 11.8.4 Strategic Initiatives
- 11.9 Cegedim Health Data
- 11.9.1 Company Overview
- 11.9.2 Financial Performance
- 11.9.3 Product Benchmarking
- 11.9.4 Strategic Initiatives
- 11.10 Medpace
- 11.10.1 Company Overview
- 11.10.2 Financial Performance
- 11.10.3 Product Benchmarking
- 11.10.4 Strategic Initiatives
Chapter 12 Strategic Recommendation And Insights
- 12.1 Overview
- 12.2 Insights
- 12.3 Recommendation